Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria

KEMRI Centre for Geographic Medicine Research, Coast, P.O. Box 230-80108, Kilifi, Kenya.
Infection and immunity (Impact Factor: 4.16). 06/2008; 76(5):2240-8. DOI: 10.1128/IAI.01585-07
Source: PubMed

ABSTRACT Individuals living in areas where malaria is endemic are repeatedly exposed to many different malaria parasite antigens. Studies on naturally acquired antibody-mediated immunity to clinical malaria have largely focused on the presence of responses to individual antigens and their associations with decreased morbidity. We hypothesized that the breadth (number of important targets to which antibodies were made) and magnitude (antibody level measured in a random serum sample) of the antibody response were important predictors of protection from clinical malaria. We analyzed naturally acquired antibodies to five leading Plasmodium falciparum merozoite-stage vaccine candidate antigens, and schizont extract, in Kenyan children monitored for uncomplicated malaria for 6 months (n = 119). Serum antibody levels to apical membrane antigen 1 (AMA1) and merozoite surface protein antigens (MSP-1 block 2, MSP-2, and MSP-3) were inversely related to the probability of developing malaria, but levels to MSP-1(19) and erythrocyte binding antigen (EBA-175) were not. The risk of malaria was also inversely associated with increasing breadth of antibody specificities, with none of the children who simultaneously had high antibody levels to five or more antigens experiencing a clinical episode (17/119; 15%; P = 0.0006). Particular combinations of antibodies (AMA1, MSP-2, and MSP-3) were more strongly predictive of protection than others. The results were validated in a larger, separate case-control study whose end point was malaria severe enough to warrant hospital admission (n = 387). These findings suggest that under natural exposure, immunity to malaria may result from high titers antibodies to multiple antigenic targets and support the idea of testing combination blood-stage vaccines optimized to induce similar antibody profiles.

Download full-text


Available from: Linda M Murungi, Jul 19, 2015
  • Source
    • "The first parasite–host interactions , including attachment and parasite positioning, are mediated by numerous integral merozoite surface proteins, which are typically membrane-anchored via a cleavable glycosylphosphatidyl inositol (GPI) moiety. Together with peripheral surface proteins they also largely determine the antigenic repertoire of Plasmodium merozoites and are targets of neutralizing antibodies [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Invasive stages of Plasmodium parasites possess distinct integral and peripheral membrane proteins that mediate host cell attachment and invasion. P113 is an abundant protein in detergent-resistant high molecular weight complexes in Plasmodium schizonts, but is unusual since expression extends to gametocytes and sporozoites. In this study, we tested whether P113 performs important functions for parasite propagation in Plasmodium berghei. We show that pre-erythrocytic expression of P113 displays key signatures of upregulated in infectious sporozoites (UIS) genes, including control by the liver stage master regulator SLARP. Targeted gene deletion resulted in viable blood stage parasites that displayed no signs of blood stage growth defects. p113(-) parasites propagated normally through the life cycle until mature sporozoites, but displayed defects during natural sporozoite transmission, leading to a delay to patency in infected animals. By comparative in vitro and in vivo analysis of pre-erythrocytic development and using a xeno-diagnostic test we show that ablation of P113 results in lower sporozoite to liver stage conversion and, as a consequence, reduced merozoite output in vivo, without delaying liver stage development. We conclude that p113 is dispensable for Plasmodium life cycle progression and plays auxiliary roles during pre-erythrocytic development.
    Molecular and Biochemical Parasitology 02/2014; 193(2). DOI:10.1016/j.molbiopara.2014.03.002 · 2.24 Impact Factor
  • Source
    • "Comparing analyses based on protective thresholds with those based on conventional cutoffs Analyses using the protective threshold as a cutoff point were compared to conventional analyses where the cutoff is defined as (1) seropositivity, defined as the mean plus 3 standard deviations of negative controls and (2) high versus low antibody levels, defined previously by us as the ELISA OD level above which the risk of malaria was lower than the population's average risk of acquiring a clinical episode of malaria [6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antibodies to selected Plasmodium falciparum merozoite antigens are often reported to be associated with protection from malaria in one epidemiological cohort, but not in another. Here, we sought to understand this paradox by exploring the hypothesis that a threshold concentration of antibodies is necessary for protection. We analyzed data from two independent cohorts along the Kenyan coast, one in which antibodies to AMA1, MSP-2 and MSP-3 were associated with protection from malaria (Chonyi) and another in which this association was not observed (Junju). We used a malaria reference reagent to standardize antibody measurements across both cohorts, and applied statistical methods to derive the threshold concentration of antibodies against each antigen that best correlated with a reduced risk of malaria (the protective threshold), in the Chonyi cohort. We then tested whether antibodies in Junju reached the protective threshold concentrations observed in the Chonyi cohort. Except for children under 3 years, the age-matched proportions of children achieving protective threshold concentrations of antibodies against AMA1 and MSP-2 were significantly lower in Junju compared to Chonyi (Fishers exact test, P<0.01). For MSP-3, this difference was significant only among 4-5 year olds. We conclude that although antibodies are commonly detected in malaria endemic populations, they may be present in concentrations that are insufficient for protection. Our results have implications for the analysis and interpretation of similar data from immuno-epidemiological studies.
    Vaccine 06/2013; 31(37). DOI:10.1016/j.vaccine.2013.06.042 · 3.49 Impact Factor
  • Source
    • "The model describing the transmission dynamics of P. vivax must then include a latent class, representing those individuals who, after recovering from infection, keep a remnant of dormant liver forms, called hypnozoites (subject to reactivation at rate ω) rather than clearing all parasites while acquiring clinical immunity. Reactivation is still a rather cryptic process, and most relapses seem to result from activation of heterologous hypnozoites [14], which suggests that genotype-specific immunity somehow modulates the occurrence of relapses, much to the resemblance of how the clinical outcome of a given infection is determined [15]. Here, parameter p 1 accounts for episodes not followed by a relapse, either because no hypnozoites were formed or because the remaining hypnozoites do not reactivate during their lifespan. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Often regarded as "benign," Plasmodium vivax infections lay in the shadows of the much more virulent P. falciparum infections. However, about 1.98 billion people are at risk of both parasites worldwide, stressing the need to understand the epidemiology of Plasmodium vivax, particularly under the scope of decreasing P. falciparum prevalence and ecological interactions between both species. Two epidemiological observations put the dynamics of both species into perspective: (1) ACT campaigns have had a greater impact on P. falciparum prevalence. (2) Complete clinical immunity is attained at younger ages for P. vivax, under similar infection rates. We systematically compared two mathematical models of transmission for both Plasmodium species. Simulations suggest that an ACT therapy combined with a hypnozoite killing drug would eliminate both species. However, P. vivax elimination is predicted to be unstable. Differences in age profiles of clinical malaria can be explained solely by P. vivax's ability to relapse, which accelerates the acquisition of clinical immunity and serves as an immunity boosting mechanism. P. vivax transmission can subsist in areas of low mosquito abundance and is robust to drug administration initiatives due to relapse, making it an inconvenient and cumbersome, yet less lethal alternative to P. falciparum.
    Journal of Parasitology Research 01/2012; 2012:921715. DOI:10.1155/2012/921715
Show more